Under the deal, Boston Scientific will acquire Devoro Medical’s Wolf thrombectomy platform, a device that captures blood clots using fingerlike prongs. It was designed to remove blood clots without damaging blood vessels and while minimizing blood loss.
Boston Scientific has been an investor in Devoro Medical since 2019 and currently holds an equity stake of about 16 percent.
The company will pay $269 million for the remaining 84 percent stake not yet owned and up to an additional $67 million dependent on certain clinical and regulatory milestones.
The deal is expected to close in the fourth quarter of 2021.
Read Boston Scientific’s full news release here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
